TapewireFind a company

organization · Reporting owner

Matrix Capital Management Company, LP

Disclosed activity across 3 companies

Tapewire entity
48315
SEC CIK
0001410830

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Adaptive Biotechnologies CorpADPT · Entity 1126Director · See RemarksMarch 08, 2021March 11, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptive Biotechnologies Corp

Report date March 08, 2021 · Filed March 11, 2021

Jointly reported with GOEL DAVID E.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnotes12,309,090 Last balance in matching sequence After 2021-03-10 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rows

Row 1 · 2021-03-08 · Sale · Disposed 234,295 · Balance 12,880,795

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 2 · 2021-03-08 · Sale · Disposed 75,000 · Balance 12,805,795

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 3 · 2021-03-08 · Sale · Disposed 33,600 · Balance 12,772,195

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 4 · 2021-03-08 · Sale · Disposed 71,194 · Balance 12,701,001

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 5 · 2021-03-08 · Sale · Disposed 85,911 · Balance 12,615,090

F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 6 · 2021-03-09 · Sale · Disposed 215,698 · Balance 12,399,392

F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 7 · 2021-03-09 · Sale · Disposed 34,302 · Balance 12,365,090

F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 8 · 2021-03-10 · Sale · Disposed 25,732 · Balance 12,339,358

F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 9 · 2021-03-10 · Sale · Disposed 30,268 · Balance 12,309,090

F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect1,504 Reported balance Holding disclosure · report date 2021-03-08 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 1,504

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aura Biosciences, Inc.

Report date May 07, 2026 · Filed May 11, 2026

Jointly reported with GOEL DAVID E.

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.00001 per share (Common Stock)SEC Table I · non-derivativeIndirectSee footnotes0 Reported balance After 2026-05-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-05-07 · Sale · Disposed 6,922,870 · Balance 0

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Zentalis Pharmaceuticals, Inc.

Report date December 15, 2025 · Filed December 15, 2025

Jointly reported with GOEL DAVID E.

Section 16 reporting ended · disclosed 2025-12-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivativeIndirectSee footnotes6,459,973 Reported balance After 2025-12-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-12-15 · Sale · Disposed 7,500,000 · Balance 6,459,973

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 07, 2026 Filed May 11, 2026 20:16 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock, par value $0.00001 per share (Common Stock) 6,922,870 $5.64 $39,044,986.80
Disclosure

SEC source: 0000950142-26-001346 · es260777872_4-matrix.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
December 15, 2025 Filed Dec 15, 2025 22:24 UTC Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 SaleCommon Stock, par value $0.001 per share 7,500,000 $1.33 $9,975,000.00
Disclosure

SEC source: 0000902664-25-005288 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,459,973

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 09, 2023 Filed Nov 9, 2023 21:35 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock, par value $0.00001 per share (Common Stock) 1,560,000 $9.00 $14,040,000.00
Disclosure

SEC source: 0000902664-23-005429 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,922,870

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
June 20, 2023 Filed Jun 20, 2023 20:30 UTC Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 PurchaseCommon Stock, par value $0.001 per share 4,760,000 $22.66 $107,861,600.00
Disclosure

SEC source: 0000902664-23-003642 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 13,959,973

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
December 05, 2022 Filed Dec 7, 2022 21:30 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock, par value $0.00001 per share ("Common Stock") 1,250,000 $12.00 $15,000,000.00
Disclosure

SEC source: 0000902664-22-005061 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 5,362,870

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionSeries E Convertible Preferred Stock · Derivative 2,327,870 $0.00 $0.00
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · derivative · entry 3

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,327,870 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock 1,785,000 $14.00 $24,990,000.00
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 2

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 4,112,870

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionCommon Stock, par value $0.00001 per share ("Common Stock") 2,327,870 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,327,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 30,268 $42.38 $1,282,664.01
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 9

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,309,090

F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 25,732 $41.47 $1,067,036.56
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 8

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,339,358

F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 34,302 $41.16 $1,411,887.47
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 7

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,365,090

F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 215,698 $40.42 $8,719,332.81
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 6

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,399,392

F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 85,911 $41.62 $3,575,753.28
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 5

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,615,090

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 71,194 $41.21 $2,933,641.32
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 4

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,701,001

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 33,600 $39.97 $1,343,039.04
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 3

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,772,195

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 75,000 $39.22 $2,941,162.50
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,805,795

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 234,295 $38.22 $8,954,309.74
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,880,795

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 20, 2020 Filed Jul 22, 2020 20:15 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 2,000,000 $40.00 $80,000,000.00
Disclosure

SEC source: 0000902664-20-002761 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 13,115,090

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
January 24, 2020 Filed Jan 28, 2020 21:15 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 2,217,101 $26.50 $58,753,176.50
Disclosure

SEC source: 0000902664-20-000523 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 15,115,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries F-1 Convertible Preferred Stock · Derivative 84,359 $0.00 Strike: $10.67 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 8

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 84,359 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries F Convertible Preferred Stock · Derivative 11,154,116 $0.00 Strike: $8.97 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 7

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 11,154,116 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries E-1 Convertible Preferred Stock · Derivative 5,893,716 $0.00 Strike: $6.04 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 6

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 5,893,716 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries A Convertible Preferred Stock · Derivative 200,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 5

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 84,359 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 4

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,332,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 11,154,116 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 3

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,247,832

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 5,893,716 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 6,093,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 200,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 200,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.